Alexion Pharmaceuticals appointed David Brennan and David Anderson interim CEO and CFO, respectively.
Brennan previously served as CEO and executive director of AstraZeneca PLC and has been a member of Alexion's board since July 2014. He succeeds David Hallal, who left the company for personal reasons and also stepped down from Alexion's board.
Further, Anderson, who was previously the senior vice president and CFO of Honeywell, succeeds Vikas Sinha, who resigned as CFO to pursue other opportunities.
Both appointments are effective immediately.
Meanwhile, Alexion said its previously announced audit and finance committee investigation is nearing completion but has not yet identified any facts that would require the company to update its previously reported historical results.
The company previously said it would postpone the release of its financial statement for the quarter ended Sept. 30 as it conducted a probe into a former employee's allegations in relation to its sales practices for Soliris.